Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

262
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
262
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

932
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
932
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

88
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
88
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

963
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
963
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

316
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
316
Fundamental Mathematical Principles in Pharmacokinetics: Calculus and Graphs01:21

Fundamental Mathematical Principles in Pharmacokinetics: Calculus and Graphs

3.5K
The fundamental mathematical principles, such as calculus and graphs, play crucial roles in analyzing drug movement and determining pharmacokinetic parameters. Differential calculus examines rates of change and helps to determine the dissolution rate of drugs in biofluids, as well as how drug concentrations change over time. For instance, it can help calculate the rate of elimination of a drug from the body based on its concentration-time profile.
On the other hand, integral calculus focuses on...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Same author

A Novel Method for Studying the Pharmacokinetics of [(14) C]Umeclidinium After Application to the Axilla or Palm of Healthy Male Subjects.

Clinical and translational science·2016
Same author

Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism.

CPT: pharmacometrics & systems pharmacology·2014
Same author

Population pharmacokinetics of azithromycin in whole blood, peripheral blood mononuclear cells, and polymorphonuclear cells in healthy adults.

CPT: pharmacometrics & systems pharmacology·2014
Same author

Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects.

Antimicrobial agents and chemotherapy·2013
Same author

Probabilistic risk analysis: improving early drug development decision making.

Clinical pharmacology and therapeutics·2010

Related Experiment Video

Updated: Apr 6, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.7K

Pharmacometrics: Focus on the Patient.

T Pene Dumitrescu1, M J Fossler2, V D Schmith1

  • 1Clinical Pharmacology Modeling and Simulation, GSK RTP, North Carolina, USA.

CPT: Pharmacometrics & Systems Pharmacology
|July 31, 2015
PubMed
Summary

Pharmacometrics modeling aids drug development. Late-stage applications offer patient benefits, accelerating effective treatments for unmet medical needs while ensuring safety.

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.6K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K

Related Experiment Videos

Last Updated: Apr 6, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.7K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.6K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K

Area of Science:

  • Pharmacometrics and drug development
  • Clinical pharmacology
  • Translational medicine

Background:

  • Pharmacometrics (PMx) supports rational and efficient drug development, primarily in early stages.
  • Late-stage drug development presents significant opportunities for patient-focused applications of PMx.
  • Existing PMx applications often overlook late-stage patient benefits.

Purpose of the Study:

  • To highlight the underutilized potential of pharmacometrics in late-stage drug development.
  • To illustrate how patient-centric pharmacometric approaches can accelerate market entry for effective therapies.
  • To demonstrate the value of pharmacometrics in addressing diseases with high unmet medical needs.

Main Methods:

  • Review of existing pharmacometric methodologies.
  • Identification and description of three innovative late-stage pharmacometric case studies.
  • Focus on patient benefits, efficacy, and safety within the case studies.

Main Results:

  • Pharmacometrics offers substantial opportunities for patient benefit in late-stage development.
  • Innovative pharmacometric approaches can expedite the delivery of efficacious drugs to patients.
  • Case studies demonstrate successful application of PMx for unmet medical needs, balancing efficacy and safety.

Conclusions:

  • Late-stage pharmacometrics provides a powerful platform for patient-focused drug development.
  • Implementing innovative pharmacometric strategies accelerates access to beneficial treatments.
  • Pharmacometrics is crucial for optimizing drug development in areas of high unmet medical need.